{"id":"soluble-beta-glucan-sbg","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Mild fever or chills"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Beta-glucans are polysaccharides derived from fungal cell walls that bind to pattern recognition receptors (particularly Dectin-1 and complement receptor 3) on macrophages, neutrophils, and dendritic cells. This binding triggers downstream signaling that enhances phagocytosis, cytokine production, and overall innate immune activation, potentially improving immune defense against infections and supporting immune homeostasis.","oneSentence":"Soluble beta-glucan activates innate immune cells to enhance immune response and reduce infection risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:24.525Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune support and infection prevention in immunocompromised patients"},{"name":"Adjunctive therapy for respiratory tract infections"}]},"trialDetails":[{"nctId":"NCT01910597","phase":"PHASE1","title":"Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2013-08-01","conditions":"Advanced Solid Tumors","enrollment":10},{"nctId":"NCT02631512","phase":"PHASE4","title":"Evaluation of Woulgan in Diabetic Foot Ulcer","status":"COMPLETED","sponsor":"Biotec Pharmacon ASA","startDate":"2015-10","conditions":"Diabetic Foot Ulcers","enrollment":62},{"nctId":"NCT00533364","phase":"PHASE1, PHASE2","title":"Effect of SBG in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Biotec Pharmacon ASA","startDate":"2007-01","conditions":"Breast Cancer","enrollment":11},{"nctId":"NCT00632008","phase":"PHASE3","title":"Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Biotec Pharmacon ASA","startDate":"2007-03","conditions":"Chronic Diabetic Foot Ulcers","enrollment":122},{"nctId":"NCT00533728","phase":"PHASE1","title":"Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Biotec Pharmacon ASA","startDate":"2007-09","conditions":"Non-Hodgkin's Lymphoma","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Soluble beta-glucan (SBG)","genericName":"Soluble beta-glucan (SBG)","companyName":"Biotec Pharmacon ASA","companyId":"biotec-pharmacon-asa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Soluble beta-glucan activates innate immune cells to enhance immune response and reduce infection risk. Used for Immune support and infection prevention in immunocompromised patients, Adjunctive therapy for respiratory tract infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}